LUCD – lucid diagnostics inc. (US:NASDAQ)

News

PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Lucid Diagnostics (LUCD) had its "buy" rating reaffirmed by BTIG Research. They now have a $2.50 price target on the stock.
Lucid Diagnostics (LUCD) was upgraded by Wall Street Zen from "sell"
Lucid Diagnostics Inc. (LUCD) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Lucid Diagnostics (LUCD) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $3.00 price target on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com